Therapeutic IL-13 polypeptides
US11993639B2 · kind B2 · utility
0Cited by
9References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2021 |
| Grant date | May 28, 2024 |
| Priority date | — |
| Expiry date | Nov 23, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG09G2320/0247
- WIPO fieldAudio-visual technology
- WIPO sectorElectrical engineering
Abstract
Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.